This Drug Could End H.I.V. Why Hasn’t It?
Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened. Guests: Dr. Grant, who has been working on H.I.V. treatment and prevention for over 30 years, and Donald G. McNeil Jr., a science and health reporter for The New York Times. For more information on today’s episode, visit nytimes.com/thedaily.
Background reading: Gilead Sciences, the maker of Truvada, the only drug approved to prevent H.I.V. infection, will donate enough of the drug to supply 200,000 patients, but critics questioned the company’s motives.The high cost of drugs remains a major obstacle to ending the AIDS epidemic.Here’s more information about PrEP from the Centers for Disease Control and Prevention website.
A New York Times investigation found that the United States is actively infiltrating Russia’s electric power grid. We look at what that means for the future of cyberwarfare. Guest: David E. Sanger, a national security correspondent for The New York Times and the author of “The Perfect Weapon:...
In Hong Kong, hundreds of thousands remain in the streets, even after city officials said they would suspend the contentious extradition bill that prompted the demonstrations in the first place. We look at why the protesters still don’t trust their government. Guest: Austin Ramzy, who covers Hong...
Across Europe, populists are saying that it’s not democracy they aim to discard, but liberalism. To end our series, we returned to Germany, the country at the heart of a liberal Europe, to see if the rejection of liberalism had also taken hold there.
Guests: Katrin Bennhold, the Berlin bureau...